Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
A 61-year-old man allegedly stabbed Sunday night by his 26-year-old son in Pearl City told police his son suffers from ...
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
The research, led by Dr. Daniel Myran, a Canada Research Chair in Social Accountability at the University of Ottawa, followed ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...
A new study from ICES and University of Ottawa reveals a 21-fold increase in schizophrenia risk following emergency visits ...
Many currently available schizophrenia drugs work by blocking dopamine type 2 (D2) receptors. But these drugs offer limited efficacy while introducing side effects that make it hard for patients ...